Activation of the EGFR, KRAS and ALK oncogenes defines three different pathways of molecular pathogenesis in lung adenocarcinoma (ADC). However, many tumors lack activation of any pathway (triple-negative lung ADCs) posing a challenge for prognosis and treatment.
Introduction
Lung cancer is the leading cause of cancer death worldwide (1, 2) . Adenocarcinoma (ADC), which accounts for over 50% of non-small-cell lung cancers (NSCLCs), is the most frequent type and is increasing. Lung ADC has a heterogeneous nature in various aspects, including clinicopathological features (3) . Recent molecular studies have revealed at least three major molecular pathways for the development of lung ADC (4) (5) (6) (7) (8) . A considerable fraction (30-60%) of lung ADCs develops through acquisition of mutations either in the EGFR, KRAS, or ALK genes in a mutually exclusive manner, and the remaining lung ADCs, i.e., those without EGFR, KRAS and ALK mutations (herein designated "triple-negative ADCs"), develop with mutations of several other genes. HER2, BRAF, etc. are known to be mutated also mutually exclusively with the EGFR, KRAS and ALK genes; however, frequencies of their mutations are very low (<5%) (4-7). Therefore, genes responsible for the development of triple-negative ADCs are largely unknown.
Mutations in the EGFR gene are prevalent in females and never-smokers, and the frequencies are considerably higher in Asians (40~60%) than in Europeans/Americans (~10%) (5) (6) (7) 9) . EGFR mutations make tumor cells dependent on EGFR signaling and define patients who respond to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib (10,11). On the other hand, mutations in the KRAS gene occur predominantly in males and ever-smokers, and their frequencies are higher in Europeans/Americans (>15%) than in Asians (10%) (9) . Specific inhibitors against KRAS activity are being developed (12).
Therefore, clinicopathological features of lung ADCs with EGFR mutations (herein designated "EGFR-positive ADCs") and those with KRAS mutations (herein designated "KRAS-positive ADCs") are considerably different from each other. Recently, a small subset of EGFR-and KRAS-negative lung ADCs (~5%) was shown to have rearrangements of the ALK gene generating gene-fusion transcripts (13) , and patients with ALK rearrangements tend to be younger and have little or no smoking histories (4, (6) (7) (8) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 11, 2011; DOI: 10.1158/0008-5472. CAN-11-1403 with ALK rearrangements (herein designated "ALK-positive ADCs") are specifically sensitive to ALK TKIs, ALK-positive ADCs have been recently considered to be another subset of ADCs by considering the differences in therapeutic targets (4, (6) (7) (8) .
In contrast, clinicopathological features of triple-negative lung ADCs have not been precisely characterized, due to the lack of sufficient genetic information in these ADCs.
There have been several studies which attempted to characterize gene expression profiles in particular types of lung ADC, including EGFR-positive and
The tumors were pathologically classified according to the TNM classification of malignant tumors (18) . A total of 226 lung ADC cases subjected to expression profiling were selected from 393 stage I-II cases who underwent potential curative resection between 1998 and 2008 at the National Cancer Center Hospital as follows (19) (Supplementary Fig. 1 To improve statistical efficiency, all the 37 relapsed cases and 131 matched un-relapsed cases selected by the incidence density sampling method (20, 21) were subjected to expression profiling. In total, 226 cases, consisting of 168 stage I and 58 stage II cases, were subjected to the expression profiling.
Among the 226 cases, 204 who received complete resection (i.e., free resection margins and no involvement of mediastinal lymph nodes examined by mediastinal dissection) and did not receive postoperative chemotherapy and/or radiotherapy, unless relapsed, were subjected to survival analyses. This study was approved by the institutional review boards of the National Cancer Center.
Microarray experiments and data processing
Total RNA was extracted using TRIzol reagent (Invitrogen), purified by an RNeasy kit (Qiagen), and qualified with a model2100 bioanalyzer (Agilent). All samples showed RNA Integrity Numbers>6.0 and were subjected to microarray experiments. Two micrograms of total RNA were labeled using a 5X
MEGAscript T7 Kit (Ambion) and analyzed by Affymetrix U133Plus2.0 arrays.
The data were processed by the MAS5 algorithm, and the mean expression level of a total of 54,675 probes was adjusted to 1,000 for each sample.
Microarray data are available at National Center for Biotechnology Information
Gene Expression Omnibus (GSE31210). 
Probe selection for unsupervised clustering
One hundred and seventy-four genes (190 probes) preferentially expressed in ALK-positive and triple-negative ADCs were selected by the following criteria; probes whose expression levels were <1000 in any ADCs with EGFR or KRAS mutations, and probes whose averaged expression levels in ALK-positive and triple-negative ADCs were >1.5-fold higher than those in EGFR-positive and KRAS-positive ADCs with P values<0.05 by t-test. Expression levels for these 190 probes were log-transformed and median-centered both for probes and samples, and were subjected to an unsupervised hierarchical clustering. The clustering was performed by the centroid linkage method using the Cluster 3.0 program, and the results were visualized using the Java Treeview program (22).
Mutation analyses
Genomic DNAs from all 226 lung ADCs were analyzed for EGFR and KRAS mutations by the high-resolution melting (HRM) method as described (23, 24).
Total RNAs from the 226 ADCs were examined for expression of fusion transcripts between ALK and EML4 or KIF5 using a multiplex reverse transcription-PCR (RT-PCR) method (25) .
Statistics
Cumulative survival was estimated by the Kaplan-Meier method, and differences in the survivals between two groups were analyzed by log-rank test. Associations of gene expression levels with prognosis of NSCLC patients in seven other expression profile studies were obtained from the PrognoScan database (26) . In the PrognoScan database, association of gene expression with patients' survival was evaluated by the minimum P-value approach. Briefly, patients were first arranged by expression levels of a given gene. They were then divided into high and low expression groups at all possible cutoff points, and the risk differences of any two groups were estimated by the log-rank test.
Finally, the cutoff point that gave the most pronounced P-value was selected.
Results

EGFR/KRAS/ALK mutations and clinicopathological characteristics of lung
ADCs subjected to gene expression profiling
Among 226 stage I-II lung ADCs, EGFR and KRAS mutations were mutually exclusively detected in 127 (56%) and 20 (9%) cases, respectively, and an EML4-ALK fusion gene was expressed in 11 (4.9%) cases (Table 1) . EGFR or KRAS mutations were not detected in any of the 11 cases with EML4-ALK fusion expression; thus, the occurrence of ALK rearrangements in a mutually exclusive manner with EGFR and KRAS mutations in lung ADC was confirmed. The incidence and the fraction of EGFR-, KRAS-and ALK-positive cases in this study were consistent with those in previous studies (5) (6) (7) 9, 13) . Accordingly, the remaining 68 (30%) cases were defined as "triple-negative ADCs" because of the absence of EGFR, KRAS and ALK mutations. Clinicopathological features of EGFR-positive ADCs and KRAS-positive ADCs in this study are well consistent with those in previous studies of Japanese populations (27, 28) .
Patients with ALK-positive ADCs were younger and more likely to be never-smokers, as previously indicated (4, (6) (7) (8) Table 2 ). It was noted that two probes for the ALK gene were present among them, and one of them Fig. 3 ).
Triple-negative lung ADCs with poor prognosis identified by gene expression profiling
By the unsupervised hierarchical clustering, 68 triple-negative ADCs were separated into two major groups, one containing 36 cases and the other 32 cases, designated as groups A and B, respectively ( Fig. 1) . Group A comprised cluster 1 with 11 ALK-positive ADCs. Group A cases were dominant in males, ever-smokers and advanced stages, whereas group B cases were dominant in never-smokers and early stages ( Table 1 ), indicating that group A cases comprise an aggressive type in triple-negative ADCs. Therefore, we next compared RFS and OS among the five groups of patients; groups A and B, EGFR-positive cases, KRAS-positive cases, and ALK-positive cases (Fig. 2) .
Among the 226 cases, 204 cases that received complete resection and did not receive postoperative chemotherapy and/or radiotherapy were subjected to survival analysis. Group A cases (n=32) showed the worst prognosis for both RFS and OS among the five groups ( Fig. 2A and B) . In particular, group A cases showed significantly worse prognosis (P<0.05) for both RFS and OS than group B cases (n=30) and EGFR-positive cases (n=116) by the log-rank test.
Such differences were marginally significant between group A cases and ADCs ( Fig. 2C and D) , indicating the independency of these associations with staging. Therefore, we next performed multivariate analyses on RFS and OS of these five groups (Table 3 ). In the analysis of 204 stage I-II patients, RFS and OS of group A cases were significantly worse than those of EGFR-positive and group B cases and the differences were independent of staging. HRs of ALK-positive and KRAS-positive cases were also as high as EGFR-positive and group B cases, although only the difference in RFS was statistically significant between group A cases and KRAS-positive cases. This could be also due to the small numbers of KRAS-positive and ALK-positive cases. Accordingly, multivariate analyses of 162 stage I patients further showed significant differences in RFS and OS between group A cases and EGFR-positive cases, and also between group A cases and group B cases. Since numbers of KRAS-positive cases and ALK-positive cases were small, we next compared RFS and OS between group A patients and patients in all four other groups combined ("Others" in Table 3 ). Differences in RFS as well as those in OS were highly significant and independent of staging. These results strongly indicate that group A patients comprise a distinct subclass of EGFR/KRAS/ALK-negative lung ADCs, and the prognoses of group A patients are the worst among the five groups of patients. Figure 4) . Therefore, the expression signature of these 174 genes was indicated to be useful for prognostic prediction of ADC patients, in particular of triple-negative ADC patients.
Clustering of lung ADCs with poor prognosis by gene expression profiling
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Minimum set of genes characterizing triple-negative lung ADCs with poor prognosis
The above results implied that triple-negative ADCs can be classified into two distinct subgroups by expression profiling and prognoses of these two groups are significantly different from each other. Accordingly, expression of several genes among the 174 genes was expected to be independently associated with prognosis of triple-negative ADC patients. Therefore, we next selected genes whose expression was associated with prognosis from the 174 genes evaluated by the 190 probes. To evaluate the prognostic value of each probe and to make a comparative study for association of gene expression with prognosis in other cohorts possible, we took a minimum P-value approach for grouping the patients for survival analysis due to the following reason. A database named PrognoScan was recently developed by coauthors of this study (26) . In the PrognoScan database, minimum P-values for the association of 
gene expression with prognosis of all probes in a platform are available for a number of cohorts which have been published. Therefore, it was possible to validate the present findings using data from various other cohorts by the same criteria. According to the method described previously (26) , corrected minimum P-values were calculated for each probe to control the error rate for the evaluation of the association with RFS and OS. Expression of 11 genes evaluated with 12 probes (two probes for the DEPDC1 gene) showed significant associations with both RFS and OS in 62 triple-negative ADCs and also in 46 stage I triple-negative ADCs (Table 4) . Among the 11 genes, expression of 10 genes was positively correlated with poor prognosis, whereas that of the remaining one gene, KIF19, was negatively correlated with poor prognosis.
We first selected 174 genes as being preferentially expressed in either ALK-positive ADCs or triple-negative ADCs by the criteria of "probes whose expression levels in any ADCs with EGFR or KRAS mutations were lower than the mean expression level of a total of 54,675 probes". Then, 11 of the 174 genes were further selected as being associated with prognosis of patients with triple-negative ADCs. Therefore, higher expression of several genes among The result strongly indicated that unsupervised hierarchical clustering using this 10 probe set (9 genes) would separate the patients into high-risk and low-risk groups for prognosis, and that all group A triple-negative ADC patients triple-negative cases only were separated with these 9 genes, HRs for both RFS and OS were much higher than those with separation of all the 204 cases. All the relapsed cases in group A were separated into the high-risk group in the analyses of both all the 204 cases and the 62 triple-negative cases only, supporting that triple-negative ADCs cases with poor prognosis can be selected as a high-risk group from all the ADC cases by expression profiling of these 9 genes (Fig. 3 ). This profiling further separated 162 stage I cases as well as 46
stage I triple-negative ADC cases into high-risk and low-risk groups with significantly different RFS as well as OS ( Supplementary Fig. 5 and Supplementary Table 3 ). Again, HRs for both RFS and OS were much higher in triple-negative ADC cases than in all ADC cases. Accordingly, high levels of expression in these 9 genes were concluded to be distinct characteristics of triple-negative ADCs with poor prognosis.
Validation of associations using independent expression profiling data
To validate the present findings using the data of other cohorts, we searched for expression profiling data with mutation data of the EGFR, KRAS and ALK genes in various databases. However, there has been no cohort in which expression profiles specifically in triple-negative ADCs were analyzed.
Therefore, unsupervised hierarchical clustering using these 9 genes was performed on a cohort of 117 Japanese lung ADC cases because expression profile data as well as EGFR/KRAS mutation data were available only in this cohort (32). This study included 57 ADC cases without EGFR and KRAS mutations. Although a different array platform was used, the data for all the 9 genes were available for clustering. These cases were separated into two groups of 33 cases and 24 cases (Fig. 3) . OS of the 33 cases was significantly Table 3 ). As with our cohort, the high-risk group showed a significantly higher HR of 2.73 even when all the 117 cases were analyzed together. Although ALK-mutation data were not available for this cohort, the results strongly supported that expression profiling of the 9 genes would be highly informative for prediction of prognosis of lung ADC patients, in particular patients with EGFR-and KRAS-negative ADCs.
Associations of DEPDC1 expression with prognosis of NSCLC patients
Associations of gene expression with prognosis in various cancers are available from the PrognoScan database (22). Therefore, associations of expression of these 9 genes with prognosis of NSCLC patients were examined in 7 other cohorts (Table 4) Fig. 3 ).
FOSL2 expression was associated with prognosis in 3 of the 7 cohorts, while MCM4, CD300A and UBE2S expression was associated in one cohort, respectively (Table 4) .
Discussion
In this study, we attempted to characterize ALK-positive ADCs and CAN-11-1403 in group A cases, will be also applicable as targets for therapy. DEPDC1 was previously identified as being up-regulated in bladder cancer and breast cancer (35) (36) (37) . Since DEPDC1 expression was hardly detectable in any normal tissues except testis, it has been considered as a cancer/testis antigen and also as a promising target of therapeutic drugs (35, 36) . This study demonstrated that DEPDC1 is preferentially expressed in triple-negative ADCs with poor prognosis. In the PrognoScan database, DEPDC1 expression is shown to be positively associated with poor prognosis in bladder cancer, multiple myeloma, breast cancer, glioma and melanoma. Therefore, DEPDC1 could be a novel target for diagnosis as well as therapy in various cancers, including lung ADC.
Identification of genetic alterations that occur specifically in group A cases will be also of great importance for the development of target therapy for stage I-II lung ADC patients with poor outcomes. Group A cases include males and ever-smokers as a majority (Table 1) ; therefore, group A cases were likely to carry several genetic alterations induced by tobacco carcinogens leading to poor outcomes. Identification of genetic alterations in group A ADCs will further facilitate the development of targeted therapies for lung ADCs with poor prognosis.
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